Presentation Material (Conference on Q1 FY2026 Financial Results)
Filed with TSE · · 29 pages · English
Sumitomo Pharma Co.Ltd. on 6ix
In the deck
Story so far
Earlier from Sumitomo Pharma Co.Ltd
- Matters Concerning Controlling Shareholders, Etc.
- Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
- Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change
- New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
- May 13, 2026 Conference on FY2025 Financial Results transcript（PDF/5,711KB）
Later from Sumitomo Pharma Co.Ltd
- Regarding a Report Concerning Sumitomo Pharma
- Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 billion yen Swiss Shuffle”
- Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)
- Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements
- Presentation Material (Conference on Q2 FY2026 Financial Results
Follow Sumitomo Pharma Co.Ltd into a list and get an email when it puts out news.
Follow Sumitomo Pharma Co.Ltd